HK2 and breast carcinoma: In breast cancer, the lncRNA BCAR4 was identified as a downstream target of YAP that controls cancer development, by reprogramming glucose metabolism through the transcription of two glycolysis activators, Hexokinase 2 (HK2) and PFKFB3.